Arthritis drugs move to self-administered list; watch for denial increase

Why This Topic Matters

The article is relevant because a coverage or payment classification change can quickly drive claim denials for commonly used therapies. Readers working with Medicare Part B billing can use the article to identify where denial risk may be increasing and which payer or contractor actions are driving it.

Article Sections

1. Policy change and denial impact

   Introduces the Medicare contractor policy change and the resulting denial concerns for injectable arthritis therapies. It frames the issue in the context of Part B billing and reimbursement.

2. Drugs affected and billing context

   Summarizes the therapies discussed, the way they are billed, and the specialties that commonly submit claims for them. It also notes the general clinical areas involved.

3. Self-administered drug list and contractor activity

   Describes how Medicare Administrative Contractors have been updating their self-administered drug lists and references the related professional advocacy response. It also notes state-level contractor variation.

4. Provider guidance and utilization data

   Presents general advice for handling denials and includes a utilization and denial-rate table by specialty. It provides supporting Medicare billing context without detailed instruction.